ArticleGeroScience2025
Associations between metabolomic scores and clinical outcomes in hospitalized COVID-19 patients.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Personal-MetaboHealth, an actionable health check in middle age, is improved by an effective lifestyle intervention in those at risk.BMC medicine · 2026Article
- The MetaboHealth score is 40% heritable and is influenced by frailty status, BMI, and smoking in Swedish twins.GeroScience · 2026Article
- Extreme MetaboHealth scores in three cohort studies associate with plasma protein markers for inflammation and cholesterol transport.Immunity & ageing : I & A · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The disease course and outcome of COVID-19 greatly varies between individuals. To explore which biological systems may contribute to this variation, we examined how individual metabolites and three metabolic scores relate to COVID-19 outcomes in hospitalized COVID-19 patients. The metabolome of 346 patients was measured using the 1H-NMR Nightingale platform. The association of individual metabolomic features and multi-biomarker scores, i.e. MetaboHealth, MetaboAge, and Infectious Disease Score (IDS) (higher scores reflect poorer health), with in-hospital disease course, long-term recovery, and overall survival were analyzed. Higher values for the metabolites phenylalanine (HR = 1.33, CI = 1.14-1.56), glucose (HR = 1.37, CI = 1.16-1.62) and lactate (HR = 1.38, CI = 1.16-1.63) were associated with mortality. For all three metabolic scores, higher scores were significantly associated with higher odds of a poorer in-hospital disease course (MetaboHealth: OR = 1.61, CI = 1.29-2.02; ΔMetaboAge: OR = 1.42, CI = 1.16-1.74; IDS: OR = 1.55, 1.25-1.93) and with overall survival (MetaboHealth: HR = 1.57, CI = 1.28-1.92; ΔMetaboAge: HR = 1.34, CI = 1.15-1.57; IDS: HR = 1.56, CI = 1.27-1.93). MetaboHealth and ΔMetaboAge showed a stronger association in younger patients (< 70 yrs.) than older patients. No clear patterns were found in associations between the three scores and measures of long-term recovery. In conclusion, the heterogeneity in disease course after SARS-COV2 infection may be explained either by generic biological frailty reflected by the three metabolomics scores or by glycemic control (glucose, lactate) and respiratory distress (phenylalanine).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.